Dager William E, Trujillo Toby C, Gilbert Brian W
University of California, Davis Medical Center, Sacramento, California, USA.
University of California San Francisco School of Pharmacy, San Francisco, California, USA.
Pharmacotherapy. 2023 Nov;43(11):1221-1236. doi: 10.1002/phar.2868. Epub 2023 Sep 5.
Anticoagulant therapy is commonly associated with a high incidence of avoidable adverse events, especially in the acute care setting. This has led to several initiatives by key national health care stakeholders, including specific attention to The Joint Commission's National Patient Safety Goals, to improve anticoagulation management. The subject of special populations has long been identified as challenging by clinicians with the use of anticoagulants. This is driven in part by numerous variables that can contribute to hard outcomes such as bleeding, thrombosis, length of stay, hospital re-admission, morbidity, and mortality. Despite the notable effort to improve the use of anticoagulants with numerous clinical trials, guidelines, guidance statements, and other sources of published evidence, notable difficulties continue to challenge practitioners in managing this class of medications. This is especially the case with very diverse critically ill populations where countless variables exist, many of which were never explored in trials or have historically been frequently excluded. Trials evaluating anticoagulation therapy often can only account for small portions of variables that may affect thrombosis and hemostasis, and study methods often do not reflect the constantly changing dynamic conditions seen in unique critically ill patients. Clinicians providing care to the numerous critically ill populations are faced with conditions that lead to relatively small therapeutic windows, which makes designing safe optimal anticoagulation management plans difficult when dealing with complex patients and mechanical support devices. The approach to crafting a successful management plan for anticoagulant therapy must incorporate the numerous variables that are continuously assessed and revised during the patient's time in the intensive care unit. We explore considerations and approaches when developing, assessing, and implementing an individualized or precision-based management plan that involves the use of anticoagulants in the critically ill. The skills and thought process provided will assist clinicians in managing this unique, variable, and challenging population.
抗凝治疗通常与可避免的不良事件高发相关,尤其是在急性护理环境中。这促使主要的国家医疗保健利益相关者采取了多项举措,包括特别关注联合委员会的国家患者安全目标,以改善抗凝管理。长期以来,临床医生一直认为特殊人群使用抗凝剂具有挑战性。这部分是由众多可能导致严重后果的变量驱动的,如出血、血栓形成、住院时间、医院再入院、发病率和死亡率。尽管通过众多临床试验、指南、指导声明和其他已发表的证据来源,在改善抗凝剂使用方面做出了显著努力,但显著的困难仍然困扰着从业者管理这类药物。对于非常多样化的重症患者群体来说尤其如此,其中存在无数变量,许多变量在试验中从未被探讨过,或者在历史上经常被排除在外。评估抗凝治疗的试验通常只能考虑可能影响血栓形成和止血的一小部分变量,而且研究方法往往不能反映在独特的重症患者中不断变化的动态情况。为众多重症患者提供护理的临床医生面临着导致治疗窗相对较小的情况,这使得在处理复杂患者和机械支持设备时设计安全的最佳抗凝管理计划变得困难。制定成功的抗凝治疗管理计划的方法必须纳入在患者重症监护期间持续评估和修订的众多变量。我们探讨在制定、评估和实施涉及在重症患者中使用抗凝剂的个体化或精准管理计划时的考虑因素和方法。所提供的技能和思维过程将帮助临床医生管理这一独特、多变且具有挑战性的人群。